Technical Report No. 54-3 (TR 54-3) Implementation of Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations: Annex 2: Case Studies in the Manufacturing of Pharmaceutical Drug Products
第54-3号技术报告(TR 54-3)药品和生物技术生产运营质量风险管理的实施:附件2:药品生产中的案例研究
In the highly regulated pharmaceutical industry, it is important that significant risks be formally identified, reduced, controlled, and effectively communicated throughout the supply chain and the product lifecycle. Both industry leaders and regulatory authorities understand that some degree of risk is inherent in the manufacturing and use of drug products, but they share the common goal of protecting the patient. Formal risk-management tools can be used to effectively document and communicate this control. ICH Quality Guideline Q9: Quality Risk Management presents general principles of risk management and examples of various risk management tools. However, Q9 does not provide details on how to use these tools in real-world pharmaceutical situations. This document is provided to bridge this gap using case studies from industry to illustrate how various risk management tools are applied. While there is no one way to apply quality risk management, PDA Technical Report No. 54-3, Implementation of Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations Annex 2: Case Studies in the Manufacturing of Pharmaceutical Drug Products provides specific case study examples of how to apply quality risk management to the manufacturing of pharmaceutical drug products. These case studies were chosen by the technical report team, of this supplemental annex to PDA Technical Report No. 54, Implementation of Quality Risk Management for Pharmaceutical and Biotechnology Manufacturing Operations, to illustrate the adaptability of quality risk management tools to help solve various problems, implement corrective actions, and keep processes in a state of control.